Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

Matzinger, Oscar; Duclos, F.; Bergh, A. van den; Carrié, C.; Villà, Salvador; Kitsios, Petros; Poortmans, Philip; Sundar, Santhanam; Steen-Banasik, Elzbieta M. van der; Gulybán, Ákos; Collette, Laurence; Bolla, M.

doi:10.1016/j.ejca.2009.07.009

Cited by 73 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In terms of acute GI and GU toxicities $grade 2, the rates reported from PO IMRT series are from 1.9% to 32.4% and 9-64%, respectively. 10,[24][25][26][27][28] For WP IMRT, acute GI and GU toxicities $grade 2 have been reported from 12% to 50% and 44-51.7%, respectively. 10,[28][29][30] Although the use of different toxicity scales makes comparison difficult, in our study, both PO and WP VMAT with daily CBCT-based IGRT provided acceptably low rates of acute GI and GU toxicity when compared with the results presented in other studies.…”

Section: Discussionmentioning

confidence: 99%

Comparison of dosimetric parameters and acute toxicity after whole-pelvicvsprostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer

Ishii¹,

Ogino²,

Hosokawa³

et al. 2016

BJR

View full text Add to dashboard Cite

Results: The mean rectal dose, the rectal volume receiving $30 Gy (V 30Gy ), rectal V 50Gy, the mean bladder dose, bladder V 30Gy and bladder V 50Gy were significantly increased in the WP group (p , 0.05 each); however, the rectal V 70Gy did not differ between groups (p 5 0.101), and the bladder V 70Gy was significantly lower in the WP group (p 5 0.029). The WP group experienced a significantly increased frequency of acute grade 2 diarrhoea relative to the PO group (5.9% vs 0%; p 5 0.015). No differences were seen between the WP and PO groups in terms of acute grade 2 proctitis (10.1% vs 6.7%; p 5 0.360) and genitourinary (GU) toxicity (12.6% vs 10.5%; p 5 0.620). Conclusion: Despite larger rectum and bladder volumes at low-and medium-dose levels, WP VMAT resulted in no significant increase in acute proctitis or GU toxicity when compared with PO VMAT. Advances in knowledge: This study demonstrates that whole-pelvic radiotherapy has comparable acute toxicity to those observed with prostate-only radiotherapy when VMAT with daily image guidance is used.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of dosimetric parameters and acute toxicity after whole-pelvicvsprostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer

Ishii¹,

Ogino²,

Hosokawa³

et al. 2016

BJR

View full text Add to dashboard Cite

show abstract

“…Rates of grade1 GI toxicities reported in CF-EBRT studies ranged from 16.1 to 51.1% (30)(31)(32), grade 2 from 6.3 to 20.7% and grade 3 from 0 to 9%. One CF-EBRT study neglected to stratify rates of acute GI toxicity by grade (29); it reported that 25% of patients treated EBRT experienced grade 2 or higher GI toxicity.…”

Section: Resultsmentioning

confidence: 99%

“…Rates of grade1 GU toxicity reported in CF-EBRT (n=1118) studies ranged from 28.7 to 51.9% (30)(31)(32), grade 2 from 15.6 to 41.4% and grade 3 from 1.1 to 8%. Two grade 4 acute GU toxicities were reported, a rate of 0.001% in the overall cohort.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer

Linney

Barrett

2018

View full text Add to dashboard Cite

show abstract

“…[6] Bu erken yan etkilerin hastaların yaşam kalitesini olumsuz yönde etkilediği ve bazı çalışmalarda geç yan etkilere predispozan olduğu bildirilmiştir. [7][8][9] Prostat kanseri tedavisinde IMRT tekniği ile doz yükseltilmesinin lokal ve biyokimyasal kontrol ve tedaviye bağlı toksisite açısından 3BKRT'ye göre üstünlüğü çeşitli çalışmalarla gösterilmiştir [10][11][12][13][14][15] . Bu nedenle günümüzde yüksek doz IMRT erken ve lokal ileri prostat kanserinde önerilen standart tedavidir.…”

Section: Sonuçunclassified

Acute toxicity in prostate carcinoma patients treated with kV-CBCT guided IMRT/VMAT

Özdemir¹

2014

TJ Oncol

View full text Add to dashboard Cite

obJecTIveSTo evaluate acute toxicity of image guided IMRT/VMAT in prostate carcinoma patients. MeTHodSAcute toxicities of 101 prostate carcinoma patients, treated with radical radiotherapy were evaluated. Prostate, prostate and seminal vesicles, and pelvic lymph nodes were enrolled into the treatment volume in 50, 40 and 11cases respectively. All patients were planned with Eclipse treatment planning system using dynamic IMRT/ VMAT. The median doses to the planning target volumes of prostate, seminal vesicles and pelvic lymphatics were 76Gy, 56Gy and 54Gy respectively, delivered simultaneously. All patients were observed per week during radiotherapy and at 1st and 3rd month following completion of therapy. Acute toxicities were graded according to the RTOG scoring criteria. reSULTSGrade 2 and 1genitourinary acute toxicity were observed in 3 and 57 patients, respectively. Grade1 gastrointestinal toxicity was detected in 15 patients, 3 patients developed grade1 skin reaction. Grade 1 leukopenia was detected in 2 cases. No grade 3-4 toxicity was observed. coNcLUSIoNIn prostate cancer, higher doses radiotherapy with kV-CBCT guided IMRT/VMAT technique was given more accurately and well tolerated. Expected side effects depending on size of irradiated volume with pelvic radiotherapy, were not observed.

show abstract

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

Cited by 73 publications

References 20 publications

Comparison of dosimetric parameters and acute toxicity after whole-pelvicvsprostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer

Comparison of dosimetric parameters and acute toxicity after whole-pelvicvsprostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer

Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer

Acute toxicity in prostate carcinoma patients treated with kV-CBCT guided IMRT/VMAT

Contact Info

Product

Resources

About